KEY HIGHLIGHTS- Revenue increased by 6.7% to HK$834.6 million – Gross profit grew by 12.5% to HK$465.5 million- Profit attributable to equity shareholders increased by 1.9% to HK$201.1 million amidst a notable increase in strategic investments- Recommended a final dividend of HK7.35 cents per share- Sustained momentum from core proprietary Chinese medicine brands…
Read More
